Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: II. Gram-negative bacteria

Yumiko Suzuki, Chisato Nishinari, Harumi Endo, Chieko Tamura, Keiko Jinbo, Nobuyoshi Hiramatsu, Kazumitsu Akiyama, Tsuneo Koyama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, and carbapenems. Thirty-two species 2,697 strains of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis (n=125), Escherichia coli (n=250), Citrobacter freundii (n=153), Citrobacter koseri (n=97), Klebsiella pneumoniae (n=150), Klebsiella oxytoca (n=100), Enterobacter aerogenes (n=50), Enterobacter cloacae (n=125), Serratia marcescens (n=153), Proteus mirabillis (n=103), Proteus vulgaris (n=77), Morganella morganii (n=141), Providencia spp. (P alcalifaciens, P. rettgeri, P stuartii; n=154), Pseudomonas aeruginosa (n=211), Pseudomonas putida (n=49), Burkholderia cepacia (n=102), Stenotrophomonas maltophilia (n=101), Haemophilus influenzae (n=210), Acinetobactor baumannii (n=63), Acinetobactor lwoffii (n=30), Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron; n=129), and Prevotella spp. (P. melaninogenica, P intermedia, P bivia, P oralis, P denticola; n=124). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P mirabilis, P vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. Iwoffii throughout 5 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 65-time difference during study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in the antibacterial activity of CZOP against H. influenzae was suggested.

Original languageEnglish
Pages (from-to)154-180
Number of pages27
JournalJapanese Journal of Antibiotics
Volume55
Issue number2
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Gram-Negative Bacteria
Haemophilus influenzae
Citrobacter koseri
Morganella morganii
Providencia
Klebsiella oxytoca
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Bacteroides fragilis
Serratia marcescens
cefpirome
Klebsiella pneumoniae
Pseudomonas aeruginosa
Mirabilis
Prevotella
Proteus vulgaris
Escherichia coli
Stenotrophomonas maltophilia
Burkholderia cepacia

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Suzuki, Y., Nishinari, C., Endo, H., Tamura, C., Jinbo, K., Hiramatsu, N., ... Koyama, T. (2002). Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: II. Gram-negative bacteria. Japanese Journal of Antibiotics, 55(2), 154-180.

Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000 : II. Gram-negative bacteria. / Suzuki, Yumiko; Nishinari, Chisato; Endo, Harumi; Tamura, Chieko; Jinbo, Keiko; Hiramatsu, Nobuyoshi; Akiyama, Kazumitsu; Koyama, Tsuneo.

In: Japanese Journal of Antibiotics, Vol. 55, No. 2, 2002, p. 154-180.

Research output: Contribution to journalArticle

Suzuki, Y, Nishinari, C, Endo, H, Tamura, C, Jinbo, K, Hiramatsu, N, Akiyama, K & Koyama, T 2002, 'Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: II. Gram-negative bacteria', Japanese Journal of Antibiotics, vol. 55, no. 2, pp. 154-180.
Suzuki, Yumiko ; Nishinari, Chisato ; Endo, Harumi ; Tamura, Chieko ; Jinbo, Keiko ; Hiramatsu, Nobuyoshi ; Akiyama, Kazumitsu ; Koyama, Tsuneo. / Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000 : II. Gram-negative bacteria. In: Japanese Journal of Antibiotics. 2002 ; Vol. 55, No. 2. pp. 154-180.
@article{9aa960079182451c90c2e8295e9dccda,
title = "Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: II. Gram-negative bacteria",
abstract = "The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, and carbapenems. Thirty-two species 2,697 strains of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis (n=125), Escherichia coli (n=250), Citrobacter freundii (n=153), Citrobacter koseri (n=97), Klebsiella pneumoniae (n=150), Klebsiella oxytoca (n=100), Enterobacter aerogenes (n=50), Enterobacter cloacae (n=125), Serratia marcescens (n=153), Proteus mirabillis (n=103), Proteus vulgaris (n=77), Morganella morganii (n=141), Providencia spp. (P alcalifaciens, P. rettgeri, P stuartii; n=154), Pseudomonas aeruginosa (n=211), Pseudomonas putida (n=49), Burkholderia cepacia (n=102), Stenotrophomonas maltophilia (n=101), Haemophilus influenzae (n=210), Acinetobactor baumannii (n=63), Acinetobactor lwoffii (n=30), Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron; n=129), and Prevotella spp. (P. melaninogenica, P intermedia, P bivia, P oralis, P denticola; n=124). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P mirabilis, P vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. Iwoffii throughout 5 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 65-time difference during study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in the antibacterial activity of CZOP against H. influenzae was suggested.",
author = "Yumiko Suzuki and Chisato Nishinari and Harumi Endo and Chieko Tamura and Keiko Jinbo and Nobuyoshi Hiramatsu and Kazumitsu Akiyama and Tsuneo Koyama",
year = "2002",
language = "English",
volume = "55",
pages = "154--180",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "2",

}

TY - JOUR

T1 - Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000

T2 - II. Gram-negative bacteria

AU - Suzuki, Yumiko

AU - Nishinari, Chisato

AU - Endo, Harumi

AU - Tamura, Chieko

AU - Jinbo, Keiko

AU - Hiramatsu, Nobuyoshi

AU - Akiyama, Kazumitsu

AU - Koyama, Tsuneo

PY - 2002

Y1 - 2002

N2 - The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, and carbapenems. Thirty-two species 2,697 strains of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis (n=125), Escherichia coli (n=250), Citrobacter freundii (n=153), Citrobacter koseri (n=97), Klebsiella pneumoniae (n=150), Klebsiella oxytoca (n=100), Enterobacter aerogenes (n=50), Enterobacter cloacae (n=125), Serratia marcescens (n=153), Proteus mirabillis (n=103), Proteus vulgaris (n=77), Morganella morganii (n=141), Providencia spp. (P alcalifaciens, P. rettgeri, P stuartii; n=154), Pseudomonas aeruginosa (n=211), Pseudomonas putida (n=49), Burkholderia cepacia (n=102), Stenotrophomonas maltophilia (n=101), Haemophilus influenzae (n=210), Acinetobactor baumannii (n=63), Acinetobactor lwoffii (n=30), Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron; n=129), and Prevotella spp. (P. melaninogenica, P intermedia, P bivia, P oralis, P denticola; n=124). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P mirabilis, P vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. Iwoffii throughout 5 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 65-time difference during study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in the antibacterial activity of CZOP against H. influenzae was suggested.

AB - The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, and carbapenems. Thirty-two species 2,697 strains of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis (n=125), Escherichia coli (n=250), Citrobacter freundii (n=153), Citrobacter koseri (n=97), Klebsiella pneumoniae (n=150), Klebsiella oxytoca (n=100), Enterobacter aerogenes (n=50), Enterobacter cloacae (n=125), Serratia marcescens (n=153), Proteus mirabillis (n=103), Proteus vulgaris (n=77), Morganella morganii (n=141), Providencia spp. (P alcalifaciens, P. rettgeri, P stuartii; n=154), Pseudomonas aeruginosa (n=211), Pseudomonas putida (n=49), Burkholderia cepacia (n=102), Stenotrophomonas maltophilia (n=101), Haemophilus influenzae (n=210), Acinetobactor baumannii (n=63), Acinetobactor lwoffii (n=30), Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron; n=129), and Prevotella spp. (P. melaninogenica, P intermedia, P bivia, P oralis, P denticola; n=124). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P mirabilis, P vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. Iwoffii throughout 5 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 65-time difference during study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in the antibacterial activity of CZOP against H. influenzae was suggested.

UR - http://www.scopus.com/inward/record.url?scp=0036251442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036251442&partnerID=8YFLogxK

M3 - Article

C2 - 12071094

AN - SCOPUS:0036251442

VL - 55

SP - 154

EP - 180

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 2

ER -